Research analysts at StockNews.com initiated coverage on shares of NanoViricides (NYSE:NNVC – Get Free Report) in a report issued on Tuesday. The firm set a “sell” rating on the stock.
NanoViricides Stock Up 1.8 %
NYSE NNVC opened at $1.12 on Tuesday. The stock’s 50-day simple moving average is $1.22 and its two-hundred day simple moving average is $1.16. NanoViricides has a twelve month low of $1.00 and a twelve month high of $2.00. The company has a market capitalization of $13.19 million, a price-to-earnings ratio of -1.38 and a beta of 0.68.
NanoViricides (NYSE:NNVC – Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Recommended Stories
- Five stocks we like better than NanoViricides
- Upcoming IPO Stock Lockup Period, Explained
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- 5 Top Rated Dividend Stocks to Consider
- Merger or Not, Albertson’s Companies is a Good Buy
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.
